Julie Eastland, MBA

Julie Eastland currently serves as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics, a private biopharmaceutical company focused in FGFR3 bladder cancer. She previously served as Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, helping negotiate the sale of the company to Seattle Genetics and assisting in the subsequent corporate transition. Prior to Cascadian, she served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately-held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon and Amgen. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.

Search Investor Relations